Receptor Density: Why Expression Level Changes the Pharmacology You Measure

4 days ago

4 min read

Updated: 2 days ago

The incretin drugs reshaping obesity and type 2 diabetes have taught the field that how a molecule engages its receptor matters as much as whether it does. Partial agonism and signaling bias are now part of how GLP-1R drugs are designed and compared. Both are also easy to miss, because they depend on something most assays fix in advance: how much receptor the cell expresses.

Why receptor density changes what you measure

Most recombinant GPCR assays use cells that express the receptor at high levels. That is a deliberate choice. A high receptor density gives a strong signal and a wide assay window, which makes it easier to detect activity reliably.

The trade-off is receptor reserve. When a cell carries far more receptors than it needs to reach its maximum response, a ligand only has to activate a small fraction of them to get there. Two things follow.

Efficacy is compressed. A partial agonist, one that cannot drive the receptor to a full response, can still reach the system maximum and look like a full agonist. A biased agonist, one that favors one pathway over another, can look balanced, because both readouts saturate.

Potency is inflated. Because fewer receptors are needed for a given response, the concentration-response curve shifts to the left, especially for amplified readouts like cAMP. The ligand looks more potent than it would in a physiological system. For GLP-1R, the same compound can return a picomolar EC50 in one cell line and a nanomolar EC50 in another.

None of this makes high-expression systems wrong. It means expression level is part of the experimental design, and the right level depends on the question.

Two ways to set receptor density

Inducible expression. In the inducible GLP-1R system, receptor expression is controlled by doxycycline. The same cells, with the same genetic background, can be run at high receptor density for sensitivity and then dialed down to characterize hits at lower density. Because receptor levels vary across tissues, the inducer concentration can also be set to approximate the system you want to model.

Concentration-response curves for Exendin-4 shifting as doxycycline changes GLP-1R expression

Concentration-response curves for tirzepatide shifting as doxycycline changes GLP-1R expression

Concentration-response curves for orforglipron shifting as doxycycline changes GLP-1R expression — *Figure 1: EC50 shift as doxycycline changes GLP-1R expression in the inducible system, for Exendin-4, tirzepatide and orforglipron.*

Constitutive low expression. The low-expression GLP-1R cell line carries a fixed, low receptor level designed to sit close to expected physiological density. There is nothing to titrate: it is ready to use when the goal is to characterize a ligand's pharmacology directly.

Comparison of GLP-1R expression levels across cell lines — *Figure 2: GLP-1R receptor expression levels across cell lines.*

Exendin-4 and orforglipron concentration-response curves in the low-expression GLP-1R cell line

Exendin-4 and orforglipron concentration-response curves in the medium-expression GLP-1R cell line

Exendin-4 and orforglipron concentration-response curves in the high-expression GLP-1R cell line — Figure 3: Exendin-4 and orforglipron in low, medium and high expression GLP-1R cell lines.

Both systems were tested with GLP-1, semaglutide, tirzepatide and orforglipron. They distinguish partial from full agonists, and the EC50 values match those reported in the literature and in physiological models such as pancreatic cells.

What tirzepatide showed

Tirzepatide is a useful example of why this matters. In a 2020 study, Willard and colleagues characterized tirzepatide in cell lines expressing low, medium and high levels of receptor. That approach showed that tirzepatide is not simply a dual GIP and GLP-1 receptor agonist: it acts as a full agonist at GIPR and a partial agonist at GLP-1R, and at GLP-1R it favors cAMP signaling over β-arrestin recruitment. Those properties have been proposed to contribute to its efficacy and tolerability profile.

At high receptor density, much of that would have been hidden.

At the low setting, the inducible system and the low-expression line express 1,000 to 2,000 receptors per cell (estimated by FACS), matching the receptor density of the cells used in that study, and the pharmacology matches as well.

Matching the assay to the question

High expression for sensitivity. Lower, tunable expression to see a ligand's true efficacy, potency and bias. With both available for GLP-1R, the choice of receptor density becomes part of the experiment rather than a fixed property of the cell line.

The inducible and low-expression GLP-1R systems are available from Eurofins DiscoverX, Dr. GPCR's Strategic Partner.

Hear it from the scientist who built them

Gianni Guizzunti is a principal scientist and group leader in R&D at Eurofins DiscoverX, where his team develops GPCR cell lines across cAMP, calcium, β-arrestin recruitment and internalization readouts. He walks through why expression level matters, when to use each system, and what the tirzepatide work revealed.